TaiRx Past Earnings Performance
Past criteria checks 0/6
TaiRx has been growing earnings at an average annual rate of 1.7%, while the Biotechs industry saw earnings growing at 19.2% annually. Revenues have been growing at an average rate of 25.3% per year.
Key information
1.7%
Earnings growth rate
14.8%
EPS growth rate
| Biotechs Industry Growth | 12.2% |
| Revenue growth rate | 25.3% |
| Return on equity | -27.5% |
| Net Margin | -4,177.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How TaiRx makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 5 | -212 | 44 | 173 |
| 30 Sep 23 | 6 | -211 | 45 | 171 |
| 30 Jun 23 | 6 | -209 | 46 | 169 |
| 31 Mar 23 | 7 | -210 | 47 | 169 |
| 31 Dec 22 | 7 | -212 | 49 | 168 |
| 30 Sep 22 | 6 | -193 | 47 | 151 |
| 30 Jun 22 | 6 | -174 | 46 | 133 |
| 31 Mar 22 | 5 | -150 | 47 | 109 |
| 31 Dec 21 | 5 | -126 | 48 | 84 |
| 30 Sep 21 | 4 | -119 | 48 | 77 |
| 30 Jun 21 | 3 | -113 | 48 | 70 |
| 31 Mar 21 | 3 | -136 | 47 | 95 |
| 31 Dec 20 | 3 | -159 | 46 | 119 |
| 30 Sep 20 | 3 | -198 | 47 | 126 |
| 30 Jun 20 | 3 | -237 | 49 | 134 |
| 31 Mar 20 | 3 | -227 | 47 | 126 |
| 31 Dec 19 | 3 | -218 | 46 | 119 |
| 30 Sep 19 | 2 | -212 | 45 | 144 |
| 30 Jun 19 | 2 | -205 | 43 | 169 |
| 31 Mar 19 | 2 | -207 | 41 | 173 |
| 31 Dec 18 | 2 | -210 | 39 | 177 |
| 30 Sep 18 | 1 | -183 | 38 | 150 |
| 30 Jun 18 | 0 | -156 | 36 | 124 |
| 31 Mar 18 | 0 | -143 | 36 | 110 |
| 31 Dec 17 | 0 | -130 | 36 | 95 |
| 30 Sep 17 | 0 | -121 | 35 | 87 |
| 30 Jun 17 | 0 | -111 | 34 | 78 |
| 31 Mar 17 | 0 | -115 | 36 | 82 |
| 31 Dec 16 | 0 | -119 | 38 | 85 |
| 30 Sep 16 | 0 | -118 | 36 | 87 |
| 30 Jun 16 | 0 | -117 | 34 | 88 |
| 31 Mar 16 | 0 | -105 | 30 | 80 |
| 31 Dec 15 | 0 | -93 | 26 | 72 |
| 31 Dec 14 | 0 | -130 | 20 | 112 |
| 31 Dec 13 | 1 | -32 | 3 | 30 |
Quality Earnings: 6580 is currently unprofitable.
Growing Profit Margin: 6580 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 6580 is unprofitable, but has reduced losses over the past 5 years at a rate of 1.7% per year.
Accelerating Growth: Unable to compare 6580's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 6580 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.1%).
Return on Equity
High ROE: 6580 has a negative Return on Equity (-27.46%), as it is currently unprofitable.